STOCK TITAN

Ihuman Inc Financials

IH
FY2025 annual
Revenue $115.4M -8.7% YoY
Net Income $13.6M +1.0% YoY
EPS (Diluted) $0.05 0.0% YoY
Free Cash Flow $6.6M -5.2% YoY
Source SEC Filings (10-K/10-Q) Data as of Dec 31, 2025 Currency USD FYE December

Ihuman Inc (IH) reported $115.4M in revenue for fiscal year 2025, down 8.7% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI IH FY2025

High gross margins and minimal capital needs let iHuman preserve profits even while revenue keeps shrinking.

Over the last two years, operating cash flow fell from $24.2M to $7.3M even though reported profit stayed positive. FY2025 net income still reached $13.6M, showing cash conversion is much weaker than at its peak and that expense control, not expanding demand, is doing more of the work behind profitability.

A roughly 68%-71% gross margin through the period, alongside capex of just $701K, points to an asset-light model where economics depend far more on operating expenses than on physical reinvestment. As sales declined for two straight years, operating margin compressed much more than gross margin, which suggests lower scale rather than a collapse in the underlying revenue model.

The balance sheet has become more conservative, with cash at $164.6M against total liabilities of $53.4M. That liquidity cushion matters because the recent revenue decline has not pushed the company toward outside financing, and retained earnings turned positive by FY2025 after being negative in prior years.

[ NOT FINANCIAL ADVICE ]

Financial Health Signals

Profitability Growth Leverage Liquidity CashFlow Returns 55 / 100
Financial Health Score 55/100

Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Ihuman Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Profitability
59

Ihuman Inc has an operating margin of 8.3%, meaning the company retains $8 of operating profit per $100 of revenue. This results in a moderate score of 59/100, indicating healthy but not exceptional operating efficiency. This is up from 7.8% the prior year.

Growth
11

Ihuman Inc's revenue declined 8.7% year-over-year, from $126.3M to $115.4M. This contraction results in a growth score of 11/100.

Leverage
65

Ihuman Inc carries a low D/E ratio of 0.38, meaning only $0.38 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 65/100, indicating a strong balance sheet with room for future borrowing.

Liquidity
83

With a current ratio of 3.57, Ihuman Inc holds $3.57 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 83/100.

Cash Flow
60

Ihuman Inc has a free cash flow margin of 5.8%, earning a moderate score of 60/100. The company generates positive cash flow after capital investments, but with room for improvement.

Returns
53

Ihuman Inc's ROE of 9.6% shows moderate profitability relative to equity, earning a score of 53/100. This is down from 10.3% the prior year.

Altman Z-Score Grey Zone
2.32

Ihuman Inc scores 2.32, placing it in the grey zone between 1.81 and 2.99. This signals moderate financial risk that warrants monitoring.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial
4/7

Ihuman Inc passes 4 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 3 of 4 profitability signals pass, all 1 leverage/liquidity signals pass, neither operating efficiency signal passes.

Earnings Quality Mixed
0.54x

For every $1 of reported earnings, Ihuman Inc generates $0.54 in operating cash flow ($7.3M OCF vs $13.6M net income). This mixed ratio suggests some earnings may rely on non-cash accounting items.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue
$115.4M
YoY-8.7%
5Y CAGR+7.2%

Ihuman Inc generated $115.4M in revenue in fiscal year 2025. This represents a decrease of 8.7% from the prior year.

EBITDA
$10.7M
YoY-9.1%

Ihuman Inc's EBITDA was $10.7M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 9.1% from the prior year.

Net Income
$13.6M
YoY+1.0%

Ihuman Inc reported $13.6M in net income in fiscal year 2025. This represents an increase of 1.0% from the prior year.

EPS (Diluted)
$0.05
YoY0.0%

Ihuman Inc earned $0.05 per diluted share (EPS) in fiscal year 2025. That is unchanged from the prior year.

Cash & Balance Sheet

Free Cash Flow
$6.6M
YoY-5.2%
5Y CAGR-26.9%

Ihuman Inc generated $6.6M in free cash flow in fiscal year 2025, representing cash available after capex. This represents a decrease of 5.2% from the prior year.

Cash & Debt
$164.6M
YoY+7.0%
5Y CAGR+4.5%

Ihuman Inc held $164.6M in cash as of fiscal year 2025; long-term debt is not reported for that period.

Dividends Per Share

Not reported for fiscal year 2025.

Shares Outstanding

Not reported for fiscal year 2025.

Margins & Returns

Gross Margin
67.9%
YoY-1.6pp
5Y CAGR-0.8pp

Ihuman Inc's gross margin was 67.9% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is down 1.6 percentage points from the prior year.

Operating Margin
8.3%
YoY+0.5pp
5Y CAGR+16.6pp

Ihuman Inc's operating margin was 8.3% in fiscal year 2025, reflecting core business profitability. This is up 0.5 percentage points from the prior year.

Net Margin
11.8%
YoY+1.1pp
5Y CAGR+18.9pp

Ihuman Inc's net profit margin was 11.8% in fiscal year 2025, showing the share of revenue converted to profit. This is up 1.1 percentage points from the prior year.

Return on Equity
9.6%
YoY-0.7pp
5Y CAGR+15.4pp

Ihuman Inc's ROE was 9.6% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 0.7 percentage points from the prior year.

Capital Allocation

R&D Spending
$29.8M
YoY-12.2%
5Y CAGR-0.5%

Ihuman Inc invested $29.8M in research and development in fiscal year 2025. This represents a decrease of 12.2% from the prior year.

Share Buybacks
$2.5M
YoY+86.4%

Ihuman Inc spent $2.5M on share buybacks in fiscal year 2025, returning capital to shareholders by reducing shares outstanding. This represents an increase of 86.4% from the prior year.

Capital Expenditures
$701K
YoY-31.3%
5Y CAGR-22.1%

Ihuman Inc invested $701K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 31.3% from the prior year.

IH Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

IH annual income statement
MetricFY25FY24FY23FY22FY21FY20
Revenue$115.4M-8.7%$126.3M-11.9%$143.4M+0.4%$142.9M-3.6%$148.2M+81.9%$81.5M
Cost of Revenue$37.1M-4.0%$38.6M-7.6%$41.8M-2.0%$42.7M-4.3%$44.6MN/A
Gross Profit$78.3M-10.7%$87.7M-13.7%$101.6M+1.4%$100.2M-3.3%$103.7M+85.1%$56.0M
R&D Expenses$29.8M-12.2%$33.9M-6.4%$36.3M-20.2%$45.5M-30.3%$65.2M+113.2%$30.6M
SG&A Expenses$13.1M-3.8%$13.6M-7.5%$14.7M-7.2%$15.8M+3.5%$15.3M-13.0%$17.6M
Operating Income$9.5M-3.1%$9.9M-56.3%$22.5M+39.2%$16.2M+290.0%-$8.5M-25.0%-$6.8M
Income Tax$913K-44.5%$1.6M-46.1%$3.1M-8.3%$3.3M+14569.6%-$23K-132.4%$71K
Net Income$13.6M+1.0%$13.5M-47.0%$25.5M+60.0%$15.9M+373.9%-$5.8M-1.3%-$5.7M
EPS (Diluted)$0.050.0%$0.05-44.4%$0.09+50.0%$0.06+400.0%-$0.02N/A

Not reported in any period shown, so not listed: Interest Expense.

IH Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

IH annual balance sheet
MetricFY25FY24FY23FY22FY21FY20
Total Assets$195.7M+0.6%$194.5M-4.8%$204.3M+5.7%$193.3M+11.9%$172.8M+7.7%$160.5M
Current Assets$185.7M+1.5%$183.0M-6.0%$194.7M+7.1%$181.8M+14.1%$159.3M+1.8%$156.5M
Cash & Equivalents$164.6M+7.0%$153.9M-10.0%$171.0M+12.3%$152.2M+13.4%$134.2M+1.6%$132.1M
Inventory$3.1M-4.9%$3.2M+38.2%$2.3M-16.1%$2.8M-37.0%$4.4M+70.2%$2.6M
Accounts Receivable$6.7M-5.6%$7.1M-16.8%$8.6M-25.8%$11.5M+31.1%$8.8M-26.3%$11.9M
Total Liabilities$53.4M-15.1%$62.9M-9.4%$69.4M-15.1%$81.8M+5.8%$77.3M+24.7%$62.0M
Current Liabilities$52.0M-15.1%$61.3M-11.3%$69.1M-15.0%$81.3M+7.3%$75.8M+23.9%$61.2M
Total Equity$142.3M+8.1%$131.6M-2.4%$134.9M+20.9%$111.6M+16.9%$95.5M-3.1%$98.5M
Retained Earnings$7.6M+232.0%-$5.8M+70.8%-$19.8M+57.5%-$46.6M+29.9%-$66.4M-12.2%-$59.2M

Not reported in any period shown, so not listed: Goodwill, Long-Term Debt.

IH Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

IH annual cash flow statement
MetricFY25FY24FY23FY22FY21FY20
Operating Cash Flow$7.3M-8.5%$8.0M-66.9%$24.2M-11.3%$27.3M+355.7%$6.0M-82.5%$34.2M
Capital Expenditures$701K-31.3%$1.0M+11.2%$917K-4.0%$955K-81.1%$5.1M+107.7%$2.4M
Free Cash Flow$6.6M-5.2%$7.0M-70.0%$23.3M-11.5%$26.4M+2735.4%$930K-97.1%$31.7M
Investing Cash Flow$5.8M+180.2%-$7.2M-688.2%-$917K+80.7%-$4.8M+5.0%-$5.0M-105.6%-$2.4M
Financing Cash Flow-$8.0M+42.8%-$14.0M-952.8%-$1.3M-31.9%-$1.0M-1676.6%$64K-99.9%$87.7M
Dividends Paid$5.6M+15.7%$4.8MN/AN/AN/AN/A
Share Buybacks$2.5M+86.4%$1.3M-1.9%$1.3M+33.2%$1.0M+3780.8%$26KN/A

IH Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples.

IH annual financial ratios
MetricFY25FY24FY23FY22FY21FY20
Gross Margin67.9%-1.6pp69.4%-1.4pp70.8%+0.7pp70.1%+0.2pp69.9%+1.2pp68.7%
Operating Margin8.3%+0.5pp7.8%-7.9pp15.7%+4.4pp11.3%+17.1pp-5.7%+2.6pp-8.4%
Net Margin11.8%+1.1pp10.7%-7.1pp17.8%+6.6pp11.1%+15.1pp-3.9%+3.1pp-7.0%
Return on Equity9.6%-0.7pp10.3%-8.6pp18.9%+4.6pp14.3%+20.4pp-6.1%-0.3pp-5.8%
Return on Assets7.0%0.0pp6.9%-5.5pp12.5%+4.2pp8.2%+11.6pp-3.4%+0.2pp-3.6%
Current Ratio3.57+0.6x2.98+0.2x2.82+0.6x2.23+0.1x2.10-0.5x2.56
Debt-to-Equity0.38-0.1x0.480.0x0.51-0.2x0.73-0.1x0.81+0.2x0.63
FCF Margin5.8%+0.2pp5.5%-10.7pp16.3%-2.2pp18.4%+17.8pp0.6%-38.3pp38.9%

Similar Companies

Frequently Asked Questions

What is Ihuman Inc's annual revenue?

Ihuman Inc (IH) reported $115.4M in total revenue for fiscal year 2025. This represents a -8.7% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Ihuman Inc's revenue growing?

Ihuman Inc (IH) revenue declined by 8.7% year-over-year, from $126.3M to $115.4M in fiscal year 2025.

Is Ihuman Inc profitable?

Yes, Ihuman Inc (IH) reported a net income of $13.6M in fiscal year 2025, with a net profit margin of 11.8%.

Ihuman Inc (IH) reported diluted earnings per share of $0.05 for fiscal year 2025. That is unchanged from the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Ihuman Inc (IH) had EBITDA of $10.7M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

Ihuman Inc (IH) had a gross margin of 67.9% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

Ihuman Inc (IH) had an operating margin of 8.3% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

Ihuman Inc (IH) had a net profit margin of 11.8% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

Ihuman Inc (IH) has a return on equity of 9.6% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

Ihuman Inc (IH) generated $6.6M in free cash flow during fiscal year 2025. This represents a -5.2% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

Ihuman Inc (IH) generated $7.3M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

Ihuman Inc (IH) had $195.7M in total assets as of fiscal year 2025, including both current and long-term assets.

Ihuman Inc (IH) invested $701K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

Ihuman Inc (IH) invested $29.8M in research and development during fiscal year 2025.

Yes, Ihuman Inc (IH) spent $2.5M on share buybacks during fiscal year 2025, returning capital to shareholders by reducing shares outstanding.

Ihuman Inc (IH) had a current ratio of 3.57 as of fiscal year 2025, which is generally considered healthy.

Ihuman Inc (IH) had a debt-to-equity ratio of 0.38 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

Ihuman Inc (IH) had a return on assets of 7.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

Ihuman Inc (IH) has an Altman Z-Score of 2.32, placing it in the Grey Zone (moderate risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

Ihuman Inc (IH) has a Piotroski F-Score of 4 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Ihuman Inc (IH) has an earnings quality ratio of 0.54x, considered mixed quality. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Ihuman Inc (IH) scores 55 out of 100 on our Financial Health Score, indicating moderate standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.

Back to top